NFKB1 and colorectal carcinoma: Co-treatment of cells with TNF-α and NF-kB inhibitor bortezomib (BZ) decreased the expression of VEGF-A back to control levels compared to TNF-α treatment alone (Figure 12), supporting a role for NF-kB in regulating the expression of VEGF-A in CRC cells.